We are live on ! Find out more
FCMV

Foresite Capital Management V Portfolio holdings

AUM $271M
1-Year Est. Return 309.87%
This Fund
S&P 500
This Quarter Est. Return
-28.02%
1 Year Est. Return
+309.87%
3 Year Est. Return
+356.88%
5 Year Est. Return
+250.56%
10 Year Est. Return
–
AUM
$245M
AUM Growth
-$162M
Cap. Flow
-$16.5M
Cap. Flow %
-6.73%
Top 10 Hldgs %
90.75%
Holding
17
New
1
Increased
1
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
HIMS icon
Hims & Hers Health
HIMS
+$4.95M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$2.75M

Top Sells

Rank Stock Value
1
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$14.1M
2
HLTH
Cue Health Inc. Common Stock
HLTH
+$6.13M
3
CGEM icon
Cullinan Oncology
CGEM
+$2.03M
4
IVVD icon
Invivyd
IVVD
+$1.92M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
2 Financials 1.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRDS
1
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$67.9M 27.72%
9,400,515
– –
THRX
2
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$37M 15.13%
3,212,732
– –
SLGC
3
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$29.9M 12.2%
3,726,472
-1,600,000
-30% -$14.1M
ACRS icon
4
Aclaris Therapeutics
ACRS
$743M
$21.7M 8.86%
1,258,243
– –
HIMS icon
5
Hims & Hers Health
HIMS
$6.26B
$14.4M 5.89%
2,706,922
+1,000,000
+59% +$4.95M
ACET icon
6
Adicet Bio
ACET
$84.7M
$13.6M 5.55%
42,500
– –
QSI icon
7
Quantum-Si Incorporated
QSI
$157M
$11M 4.48%
2,342,061
– –
CGEM icon
8
Cullinan Oncology
CGEM
$1.08B
$10.4M 4.24%
992,507
-150,499
-13% -$2.03M
KNTE
9
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$9.85M 4.02%
875,001
– –
IVVD icon
10
Invivyd
IVVD
$171M
$6.53M 2.67%
1,431,826
-313,234
-18% -$1.92M
CMPX icon
11
Compass Therapeutics
CMPX
$349M
$6.03M 2.46%
4,400,000
– –
RACB
12
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$4.88M 1.99%
500,000
– –
IRON icon
13
Disc Medicine
IRON
$3.03B
$3.38M 1.38%
81,171
– –
HLTH
14
DELISTED
Cue Health Inc. Common Stock
HLTH
$3.16M 1.29%
490,546
-677,236
-58% -$6.13M
ENTA icon
15
Enanta Pharmaceuticals
ENTA
$378M
$3.01M 1.23%
+42,250
New +$2.75M
ME
16
DELISTED
23andMe Holding Co
ME
$1.56M 0.64%
20,346
– –
PHVS icon
17
Pharvaris
PHVS
$2.37B
$619K 0.25%
34,142
– –

Similar funds

MAM
Mullooly Asset Management Wall Township, New Jersey $271M AUM 16.93% 1-Year Est. Return
MLM
Mount Lucas Management Newtown, Pennsylvania $271M AUM 25.49% 1-Year Est. Return
MCM
Moerus Capital Management New York $271M AUM 58.78% 1-Year Est. Return
RP
Ravenswood Partners Mclean, Virginia $271M AUM
PCM
Punch Card Management Winter Park, Florida $271M AUM 11.49% 1-Year Est. Return
S
Siemens Munich, Germany $272M AUM 183.71% 1-Year Est. Return
VW
Veridan Wealth West Linn, Oregon $270M AUM
TP
TritonPoint Partners Chevy Chase, Maryland $272M AUM

Foresite Capital Management V's Q1 2022 Portfolio in Review

As of Q1 2022, Foresite Capital Management V held 17 positions worth $245M, down 40% from $407M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Foresite Capital Management V withdrew a net $16.5M in Q1 2022, reducing 4 holdings. Its largest reduction was SomaLogic, Inc. Class A Common Stock, cutting an estimated $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Foresite Capital Management V opened a new position in Enanta Pharmaceuticals worth $3.01M.

  • Foresite Capital Management V's largest Q1 2022 buy was Enanta Pharmaceuticals: 42,250 shares worth $3.01M.
  • Foresite Capital Management V added most to Hims & Hers Health in Q1 2022, an estimated $4.95M increase.
  • Foresite Capital Management V's biggest Q1 2022 reduction was SomaLogic, Inc. Class A Common Stock, cutting an estimated $14.1M.
  • Foresite Capital Management V's ten largest holdings make up 91% of its $245M portfolio in Q1 2022.
  • Foresite Capital Management V opened 1 new position and closed 0 in Q1 2022.
  • Foresite Capital Management V's portfolio value fell 40% quarter-over-quarter to $245M.

Based on Foresite Capital Management V's 13F filing for Q1 2022, filed 13 May 2022.